News

Lorazepam was associated with worse survival outcomes for patients with pancreatic cancer, while alprazolam was associated with improved outcomes.

Adagrasib elicited a 1-year overall survival rate of 52.8% and 2-year rate of 31.3%.

The median progression-free survival with iruplinalkib was 27.70 months vs 14.62 months with crizotinib.

The FDA has approved motixafortide in combination with filgrastim to mobilize hematopoietic stem cells in multiple myeloma transplantation, based on findings from the phase 3 GENESIS trial.

Although survival is improving overall, disparities continue to grow.

A total of 58.5% of patients who received luspatercept remained red blood cell (RBC) transfusion independent for 12 weeks or more.

Elizabeth Aronson, MSN, FNP-BCN, OCN, discusses how the recent approvals of elranatamab and talquetamab are changing the treatment landscape for patients with multiple myeloma.

The rate of minimal residual disease-negative complete remission was 34.4% with ponatinib vs 16.7% with imatinib.

Stronger interventions are needed to improve adjuvant treatment rates among breast cancer survivors.

The 2-year event-free survival rate among patients with muscle-invasive urothelial carcinoma was 75.7%.

Younger populations and African American patients are most impacted.

White patients have the oldest average at diagnosis at 64.5 years, whereas Hispanic or Latino patients have the youngest average age at 57.2 years.

In 2021, immune checkpoint inhibitors were used by 12.1% of patients with cancer—however, these agents represent 36.2% of all oncology medication costs.

Patients with heavily pretreated relapsed/refractory multiple myeloma, including those with lenalidomide and pomalidomide-refractory disease, showed encouraging responses with mezigdomide plus dexamethasone.

Patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy may benefit from the addition of pembrolizumab to COPDAC-28 consolidation.

The median progression-free survival among patients in the intention-to-treat population who received niraparib was 24.8 months compared with 8.3 months among patients who received placebo.

What happens when there is a shortage of chemotherapy drugs? How will this affect patients?

Linda Bloom, MPA, RN, OCN, explains how amplifiers and audio interpreter tablets can be vital resources during cancer care.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

It is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.

Effective interventions exist for cancer-related sexual dysfunction, but higher-quality research is still needed to optimize management.

Black patients with multiple myeloma may be at a higher-risk for bortezomib-induced peripheral neuropathy compared with non-Black patients.

The FDA has approved luspatercept to treat anemia in patients with lower-risk myelodysplastic syndromes.

Jennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.

The program’s initiative aims to identify those at increased risk for cancer through assessment and testing and then formulate a personalized evidence-based cancer surveillance or screening plan.

Cabozantinib and atezolizumab led to a statistically significant progression-free survival improvement in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease.

Selpercatinib led to improved progression-free survival in patients with advanced or metastatic RET-mutant medullary thyroid cancer.

The FDA has granted enzalutamide priority review designation based on data from the phase 3 EMBARK trial.

A retrospective study highlights the need to examine sustainable reimbursement structures for telehealth services.

It is anticipated that health care spending will grow by an annual average of 5.4% over the next 8 years.